The Effect Of Aspirin On Survival in in Patients Undergoing Chronic Hemodialysis
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT02261025 |
|
Recruitment Status :
Completed
First Posted : October 9, 2014
Last Update Posted : October 23, 2014
|
Sponsor:
Shanghai Jiao Tong University School of Medicine
Information provided by (Responsible Party):
Hui Min Jin, Shanghai Jiao Tong University School of Medicine
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Brief Summary:
The aim of present study is to examine the effect of low-dose aspirin on the incidence of cardiovascular events and mortality in patients undergoing chronic hemodialysis.
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Hemodialysis | Drug: acetylsalicylic acid | Not Applicable |
This study prospectively evaluate the impacts of low dose aspirin on survival and cardio-cerebral vascular events in a large cohort of Chinese patients undergoing chronic hemodialysis. Between January 2008, consecutive patients with hemodialysis with aspirin were enrolled.We examine the association of aspirin with all-cause mortality in patients matched by propensity scores using the Kaplan-Meier method and Cox models in "intention-to-treat" analyses.The secondary endpoint was rate of cardio-cerebral events.
| Study Type : | Interventional (Clinical Trial) |
| Actual Enrollment : | 410 participants |
| Allocation: | Non-Randomized |
| Intervention Model: | Parallel Assignment |
| Masking: | None (Open Label) |
| Primary Purpose: | Prevention |
| Official Title: | The Effect Of Aspirin On Survival in in Patients Undergoing Chronic Hemodialysis |
| Study Start Date : | January 2008 |
| Actual Primary Completion Date : | September 2014 |
| Actual Study Completion Date : | September 2014 |
Resource links provided by the National Library of Medicine
MedlinePlus related topics:
Dialysis
Drug Information available for:
Aspirin
| Arm | Intervention/treatment |
|---|---|
|
Experimental: Aspirin group
Aspirin 75-100mg,per day,oral
|
Drug: acetylsalicylic acid
75-100mg,per day
Other Name: Aspirin |
|
No Intervention: non-aspirin group
No interventions
|
Primary Outcome Measures :
- survival rate [ Time Frame: 5 years ]
Secondary Outcome Measures :
- cardio-cerebral event [ Time Frame: 5 years ]
Information from the National Library of Medicine
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years to 85 Years (Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
All patients aged 18 to 85, undergoing chronic hemodialysis, who have none of the following exclusion criteria.
Exclusion Criteria:
History of gastric or duodenal ulcers Known allergy to aspirin or other NSAIDs
-
No Contacts or Locations Provided
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
| Responsible Party: | Hui Min Jin, Shanghai Jiao Tong University School of Medicine |
| ClinicalTrials.gov Identifier: | NCT02261025 |
| Other Study ID Numbers: |
20120308 |
| First Posted: | October 9, 2014 Key Record Dates |
| Last Update Posted: | October 23, 2014 |
| Last Verified: | October 2014 |
Keywords provided by Hui Min Jin, Shanghai Jiao Tong University School of Medicine:
|
aspirin |
Additional relevant MeSH terms:
|
Aspirin Anti-Inflammatory Agents, Non-Steroidal Analgesics, Non-Narcotic Analgesics Sensory System Agents Peripheral Nervous System Agents Physiological Effects of Drugs Anti-Inflammatory Agents |
Antirheumatic Agents Fibrinolytic Agents Fibrin Modulating Agents Molecular Mechanisms of Pharmacological Action Platelet Aggregation Inhibitors Cyclooxygenase Inhibitors Enzyme Inhibitors Antipyretics |

